Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Mar 27, 5:52AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT).

Claim 30% Off TipRanks Premium

Neurogene (NGNE)

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of $70.00. The company’s shares closed last Wednesday at $22.03, close to its 52-week low of $13.47.

According to TipRanks.com, Kapoor is a 4-star analyst with an average return of 8.5% and a 38.7% success rate. Kapoor covers the Healthcare sector, focusing on stocks such as Lexeo Therapeutics, Inc., BioMarin Pharmaceutical, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurogene with a $91.50 average price target, implying a 330.8% upside from current levels. In a report issued on March 23, LifeSci Capital also maintained a Buy rating on the stock with a price target.

See today’s best-performing stocks on TipRanks >>

Vertex Pharmaceuticals (VRTX)

In a report released yesterday, Paul Matteis from Stifel Nicolaus assigned a Hold rating to Vertex Pharmaceuticals, with a price target of $466.00. The company’s shares closed last Wednesday at $454.97.

According to TipRanks.com, Matteis is a 5-star analyst with an average return of 13.9% and a 47.7% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Rapport Therapeutics, Inc., and KalVista Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vertex Pharmaceuticals with a $555.65 average price target, a 23.7% upside from current levels. In a report issued on March 10, Needham also maintained a Hold rating on the stock with a $460.00 price target.

Sarepta Therapeutics (SRPT)

In a report released today, Gil Blum from Needham maintained a Sell rating on Sarepta Therapeutics. The company’s shares closed last Wednesday at $23.77.

According to TipRanks.com, Blum is a 4-star analyst with an average return of 8.0% and a 38.8% success rate. Blum covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Mereo Biopharma Group Plc, and Recursion Pharmaceuticals. ;'>

Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $20.53, representing a 3.9% upside. In a report released yesterday, Citi also maintained a Sell rating on the stock with a $13.00 price target.

Read More on NGNE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).